67 related articles for article (PubMed ID: 24327148)
1. [Research on molecular markers for epigenetic changes in myeloid malignancies].
Li L; Sun XM
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Dec; 30(6):687-92. PubMed ID: 24327148
[TBL] [Abstract][Full Text] [Related]
2. The role of mutations in epigenetic regulators in myeloid malignancies.
Shih AH; Abdel-Wahab O; Patel JP; Levine RL
Nat Rev Cancer; 2012 Sep; 12(9):599-612. PubMed ID: 22898539
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Epigenetic Modifications in Myeloid Malignancies.
Venney D; Mohd-Sarip A; Mills KI
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065087
[TBL] [Abstract][Full Text] [Related]
4. [Epigenetic dysregulation in myelodysplastic syndromes].
Sashida G
Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
[TBL] [Abstract][Full Text] [Related]
5. The evolving molecular genetic landscape in acute myeloid leukaemia.
Sanders MA; Valk PJ
Curr Opin Hematol; 2013 Mar; 20(2):79-85. PubMed ID: 23380602
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies.
McDevitt MA
Semin Oncol; 2012 Feb; 39(1):109-22. PubMed ID: 22289497
[TBL] [Abstract][Full Text] [Related]
7. [Mutations of epigenetic regulator genes and myeloid malignancies].
Muto T; Sashida G; Oshima M; Iwama A
Rinsho Ketsueki; 2015 Nov; 56(11):2287-94. PubMed ID: 26666714
[TBL] [Abstract][Full Text] [Related]
8. The role of mutations in epigenetic regulators in myeloid malignancies.
Woods BA; Levine RL
Immunol Rev; 2015 Jan; 263(1):22-35. PubMed ID: 25510269
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
[TBL] [Abstract][Full Text] [Related]
10. Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.
Soriano G; Heaney M
Curr Opin Hematol; 2013 Mar; 20(2):169-75. PubMed ID: 23298878
[TBL] [Abstract][Full Text] [Related]
11. The role of ASXL1 in hematopoiesis and myeloid malignancies.
Asada S; Fujino T; Goyama S; Kitamura T
Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
[TBL] [Abstract][Full Text] [Related]
12. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
13. Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations.
Larsson N; Lilljebjörn H; Lassen C; Johansson B; Fioretos T
Eur J Haematol; 2012 Feb; 88(2):136-43. PubMed ID: 21933280
[TBL] [Abstract][Full Text] [Related]
14. Disruption of
Gjini E; Jing CB; Nguyen AT; Reyon D; Gans E; Kesarsing M; Peterson J; Pozdnyakova O; Rodig SJ; Mansour MR; Joung K; Look AT
Dis Model Mech; 2019 May; 12(5):. PubMed ID: 31064769
[TBL] [Abstract][Full Text] [Related]
15. DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients.
Shivarov V; Gueorguieva R; Stoimenov A; Tiu R
Leuk Res; 2013 Nov; 37(11):1445-50. PubMed ID: 23962568
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
[TBL] [Abstract][Full Text] [Related]
17. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy.
Fathi AT; Abdel-Wahab O
Adv Hematol; 2012; 2012():469592. PubMed ID: 21811504
[TBL] [Abstract][Full Text] [Related]
18. The epigenomics revolution in myelodysplasia: a clinico-pathological perspective.
Tan PT; Wei AH
Pathology; 2011 Oct; 43(6):536-46. PubMed ID: 21881538
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
20. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Gelsi-Boyer V; Trouplin V; Adélaïde J; Bonansea J; Cervera N; Carbuccia N; Lagarde A; Prebet T; Nezri M; Sainty D; Olschwang S; Xerri L; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
Br J Haematol; 2009 Jun; 145(6):788-800. PubMed ID: 19388938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
